Procos SpA is extremely glad to announce the GMP approval of the new manufacturing section R10bis by the Italian Authority (AIFA).
These 4 newly completed production rigs provide additional 110 m3 reactor capacity to Procos site for a total of 26 rigs and 560 m3 of capacity.Procos SpA is extremely glad to announce the GMP approval of the new manufacturing section R10bis by the Italian Authority (AIFA).
These 4 newly completed production rigs provide additional 110 m3 reactor capacity to Procos site for a total of 26 rigs and 560 m3 of capacity.
The brand-new modules are ranging from 2500 L to 6300 L, stainless steel and glass lined reactors (perfectly suitable for mid-large-scale APIs and intermediates) including filter drier, centrifuges with dynamic driers in order to tackle the potential different needs in the product isolation.
The brand-new modules are ranging from 2500 L to 6300 L, stainless steel and glass lined reactors (perfectly suitable for mid-large-scale APIs and intermediates) including filter drier, centrifuges with dynamic driers in order to tackle the potential different needs in the product isolation.
About Procos S.p.A.
Procos S.p.A. is a wholly owned subsidiary of the Japanese company, CBC Co. Ltd Group, specializing in the development, scale-up and production of Active Pharmaceutical Ingredients (APIs), advanced intermediates and related services for the pharmaceutical industry.
A locally rooted company yet part of an international network, with commercial offices in key strategic geographies.
More info at www.procos.it
